Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference
09 janv. 2025 08h00 HE
|
Daré Bioscience, Inc.
The panel will discuss the value proposition for investing in women’s health. J.P. Morgan is hosting a three-panel women’s health series at this year’s conference to highlight the importance of...
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)
16 déc. 2024 08h00 HE
|
Daré Bioscience, Inc.
FSAD is clinically analogous to erectile dysfunction in men.To date, there are no FDA-approved pharmacological treatments for FSAD; Daré’s Sildenafil Cream has the potential to receive the first FDA...
Daré Bioscience Announces Publication in Sexual Medicine of Positive Findings from Demographic, Behavioral and Medication Use Subgroup Analyses in the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
10 déc. 2024 08h00 HE
|
Daré Bioscience, Inc.
SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced that additional data from the...
Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
04 déc. 2024 08h00 HE
|
Daré Bioscience, Inc.
Daré Bioscience’s DARE-LARC1 Platform Technology has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases Strategic Process Underway to Explore Partnering...
Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update
14 nov. 2024 16h01 HE
|
Daré Bioscience, Inc.
Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate – pivotal Phase 3...
Daré Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene® Pivotal Study Clinical Trial Sites
13 nov. 2024 08h00 HE
|
Daré Bioscience, Inc.
- Grant funds will support activities that will aid in the identification and development of a novel non-hormonal intravaginal contraceptive product candidate. - Grant will also provide funding to...
Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024
07 nov. 2024 08h00 HE
|
Daré Bioscience, Inc.
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, will host a conference call and live webcast at 4:30...
Daré Bioscience Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health
23 oct. 2024 12h30 HE
|
Daré Bioscience, Inc.
DARE-HPV is a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease which could change the treatment paradigm for clinical HPV management. Essentially all...
Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC
21 oct. 2024 08h05 HE
|
Daré Bioscience, Inc.
SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced it entered into a $15 million common...
Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
26 août 2024 08h00 HE
|
Daré Bioscience, Inc.
Published data show that topical Sildenafil Cream, 3.6% was safe and well tolerated by women and their partners across 1,357 sexual experiences. Use of topical Sildenafil Cream, 3.6% did not...